scholarly journals THE EPIDEMIOLOGY OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS AMONG ARAB AMERICANS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S463-S463
Author(s):  
Florence Dallo ◽  
Tiffany Kindratt
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The United States ◽  
Arab Americans ◽  
Foreign Born ◽  
Chi Square ◽  
P Values ◽  
Future Studies ◽  
Interview Survey ◽  
Age And Sex

Abstract In the United States (U.S.), Alzheimer’s Disease and Related Dementias (ADRD) afflict over 4.7 million individuals ages 65 or older. Most studies compare the prevalence of ADRD between minorities and whites. Arab Americans are a subgroup of whites, and ADRD is not understood among Arab Americans. The overall goal of this study is to estimate the prevalence of and risk factors for ADRD among Arab Americans ages 45 or older compared to non-Hispanic whites, non-Hispanic blacks, Hispanics and Asian Americans. Data for 2000-2017 from the National Health Interview Survey (NHIS) using the region of birth question was be used (N=222,219). Percents, chi-square and logistic regression will be estimated. Age- and sex-adjusted prevalence of ADRD was 10.3% for foreign-born Arab Americans compared to approximately 7.5% for US-born non-Hispanic whites (NHW), blacks and Asians. The prevalence of ADRD was 8.6% for Hispanics (all p-values <.0001). When controlling for age and sex, Arab Americans were 1.4 times (OR=1.02,1.93) more likely to have ADRD compared to US-born NHW. This is the first study to focus on ADRD among Arab Americans and the findings suggest ADRD is a burden in this population. Future studies should capture other generations of Arab Americans to better understand the trend of ADRD among this understudied, often invisible population.

scholarly journals PREVALENCE AND RISK FACTORS FOR ADRD AMONG ARAB AMERICANS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S543-S543
Author(s):  
Florence Dallo
Keyword(s):  
United States ◽  
Risk Factors ◽  
National Health Interview Survey ◽  
The United States ◽  
Arab Americans ◽  
Foreign Born ◽  
P Values ◽  
Future Studies ◽  
Interview Survey ◽  
Age And Sex

Abstract In the United States (U.S.), Alzheimer’s Disease and Related Dementias (ADRD) afflict over 4.7 million individuals ages 65 or older. Arab Americans are a subgroup of whites in which ADRD is not well understood. This study estimates prevalence and risk factors for ADRD among Arab Americans ages 45 or older. Data for 2000-2017 from the National Health Interview Survey (NHIS) using the region of birth question was used (N=222,219). The age- and sex-adjusted prevalence of ADRD was 10.3% for foreign-born Arab Americans compared to approximately 7.5% for US-born non-Hispanic whites (NHW), blacks and Asians. The prevalence of ADRD was 8.6% for Hispanics (all p-values <.0001). When controlling for age and sex, Arab Americans were 1.4 times (OR=1.02,1.93) more likely to have ADRD compared to US-born NHW. Future studies should capture other generations of Arab Americans to better understand the trend of ADRD among this understudied, often invisible population.

scholarly journals Prevalence of Self-Reported Cognitive Impairment among Arab American Immigrants in the United States

2020 ◽  
Author(s):  
Florence J Dallo ◽  
Tiffany B Kindratt ◽  
Laura Zahodne
Keyword(s):  
Cognitive Impairment ◽  
Ethnic Disparities ◽  
The United States ◽  
Arab American ◽  
Foreign Born ◽  
Logistic Regression Models ◽  
Explanatory Factors ◽  
Interview Survey ◽  
Design And Methods ◽  
Age And Sex

Abstract Background and Objectives Studies evaluating self-reported cognitive impairment among Arab American immigrants have not been conducted. Our objective was two-fold: 1) estimate and compare the age- and sex-adjusted prevalence of self-reported cognitive impairment between Arab American immigrants and US- and immigrant non-Hispanic whites, non-Hispanic blacks, Hispanics and non-Hispanic Asians and 2) examine associations between race, ethnicity and nativity status and cognitive impairment among Arab American immigrants and non-Hispanic whites (US- and foreign-born) after controlling for explanatory factors. Research Design and Methods We used 18 years (2000-2017) of National Health Interview Survey data (n=228,985; ages > 45 years). Weighted percentages, prevalence estimates, and multivariable logistic regression models were calculated. Results The age- and sex-adjusted prevalence of self-reported cognitive impairment was significantly higher among Arab American immigrants (9.7%) compared to US-born and non-Hispanic white immigrants (~7.4%). Discussion and Implications This is the first study to indicate that ethnic disparities in self-reported cognitive impairment may extend to Arab American immigrants. Additional studies need to be conducted to better understand the prevalence of cognitive impairment.

scholarly journals Arab American Cognitive Aging: Opportunities for Advancing Research on Alzheimer’s Disease Disparities

2017 ◽  
Vol 1 (3) ◽  
Author(s):  
Kristine J Ajrouch ◽  
Laura B Zahodne ◽  
Toni C Antonucci
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Ethnic Group ◽  
Cognitive Aging ◽  
The United States ◽  
Arab Americans ◽  
Arab American ◽  
Cognitive Health ◽  
Ethnic Factors ◽  
Immigration And Religion

Abstract Background and Objectives This article highlights the dearth of and need for research on Arab American cognitive aging. We propose that studying cognitive health issues among older Arab Americans provides an innovative opportunity to advance knowledge about causes and consequences of Alzheimer’s disease (AD) disparities and refine understanding of factors linked to immigrant health in the United States. Research Design and Methods Demographic information is provided on Arab Americans, who are on the cusp of being recognized by the U.S. government as a distinct ethnic group separate from whites. In the tradition of minority aging, we present a broad review of specific issues in the contemporary case of Arab Americans. Results We detail how including Arab Americans provides unique information on the importance of: (i) extending racial/ethnic group comparisons; (ii) linking social experiences to late-life cognitive health; and (iii) incorporating ethnic factors related to immigration and religion in the study of AD disparities. Discussion and Implications Studying Arab American cognitive aging provides an innovative opportunity to more fully delineate factors that create and sustain health disparities, with special insights into both causes and consequences.

Leveraging Technology in Detection of Alzheimer’s Disease: A Systematic Review (Preprint)

2019 ◽  
Author(s):  
Clemens Kruse ◽  
Britney Larson ◽  
Reagan Wilkinson ◽  
Roger Samson ◽  
Taylor Castillo
Keyword(s):  
Magnetic Resonance Imaging ◽  
United States ◽  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The United States ◽  
Diagnostic Process ◽  
Resonance Imaging ◽  
Common Cause ◽  
Key Terms

BACKGROUND Incidence of AD continues to increase, making it the most common cause of dementia and the sixth-leading cause of death in the United States. 2018 numbers are expected to double by 2030. OBJECTIVE We examined the benefits of utilizing technology to identify and detect Alzheimer’s disease in the diagnostic process. METHODS We searched PubMed and CINAHL using key terms and filters to identify 30 articles for review. We analyzed these articles and reported them in accordance with the PRISMA guidelines. RESULTS We identified 11 technologies used in the detection of Alzheimer’s disease: 66% of which used some form of MIR. Functional, structural, and 7T magnetic resonance imaging were all used with structural being the most prevalent. CONCLUSIONS MRI is the best form of current technology being used in the detection of Alzheimer’s disease. MRI is a noninvasive approach that provides highly accurate results in the diagnostic process of Alzheimer’s disease.

scholarly journals Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer’s Disease in the FIT-AD Trial

2021 ◽  
pp. 1-11
Author(s):  
Danni Li ◽  
Lin Zhang ◽  
Nathaniel W. Nelson ◽  
Michelle M. Mielke ◽  
Fang Yu
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Daily Living ◽  
Short Term ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Linear Mixed Effects ◽  
Future Studies ◽  
Rate Of Decline ◽  
And Function

Background: Utilities of blood-based biomarkers in Alzheimer’s disease (AD) clinical trials remain unknown. Objective: To evaluate the ability of plasma neurofilament light chain (NfL) to predict future declines in cognition and activities of daily living (ADL) outcomes in 26 older adults with mild-to-moderate AD dementia from the FIT-AD Trial. Methods: Plasma NfL was measured at baseline and 3 and 6 months. Cognition and ADL were assessed using the AD Assessment Scale-Cognition (ADAS-Cog) and AD Uniform Dataset Instruments and Disability Assessment for Dementia (DAD), respectively, at baseline, 3, 6, 9, and 12 months. Linear mixed effects models were used to examine the associations between baseline or change in plasma NfL and changes in outcomes. Results: Higher baseline plasma NfL was associated with greater rate of decline in ADAS-Cog from baseline to 6 months (standardized estimate of 0.00462, p = 0.02853) and in ADL from baseline to 12 months (standardized estimate of –0.00284, p = 0.03338). Greater increase in plasma NfL in short term from baseline to 3 months was associated with greater rate of decline in memory and ADL from 3 to 6 months (standardized estimate of –0.04638 [0.003], p = 0.01635; standardized estimate of –0.03818, p = 0.0435) and greater rate of decline in ADL from 3 to 12 month (standardized estimate of –0.01492, p = 0.01082). Conclusion: This study demonstrated that plasma NfL might have the potential to predict cognitive and function decline up to 12 months. However, future studies with bigger sample sizes need to confirm the findings.

380 Projected incidence of Alzheimer's disease in the United States

1996 ◽  
Vol 17 (4) ◽  
pp. S95
Author(s):  
L. Hebert ◽  
P. Scherr ◽  
L. Beckett ◽  
D. Evans
Keyword(s):  
United States ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The United States

scholarly journals The Role of Oxidative Stress-Induced Epigenetic Alterations in Amyloid-βProduction in Alzheimer’s Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
Li Zuo ◽  
Benjamin T. Hemmelgarn ◽  
Chia-Chen Chuang ◽  
Thomas M. Best
Keyword(s):  
Oxidative Stress ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Beta ◽  
Treatment Options ◽  
Memory Loss ◽  
The United States ◽  
Traditional Medicines ◽  
Progressive Neurodegeneration ◽  
Antioxidant Supplements

An increasing number of studies have proposed a strong correlation between reactive oxygen species (ROS)-induced oxidative stress (OS) and the pathogenesis of Alzheimer’s disease (AD). With over five million people diagnosed in the United States alone, AD is the most common type of dementia worldwide. AD includes progressive neurodegeneration, followed by memory loss and reduced cognitive ability. Characterized by the formation of amyloid-beta (Aβ) plaques as a hallmark, the connection between ROS and AD is compelling. Analyzing the ROS response of essential proteins in the amyloidogenic pathway, such as amyloid-beta precursor protein (APP) and beta-secretase (BACE1), along with influential signaling programs of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and c-Jun N-terminal kinase (JNK), has helped visualize the path between OS and Aβoverproduction. In this review, attention will be paid to significant advances in the area of OS, epigenetics, and their influence on Aβplaque assembly. Additionally, we aim to discuss available treatment options for AD that include antioxidant supplements, Asian traditional medicines, metal-protein-attenuating compounds, and histone modifying inhibitors.

Effect of Alzheimer’s Training on Multicultural Personal Care Aides

2008 ◽  
Vol 9 (1) ◽  
pp. 4-10 ◽  
Author(s):  
Robin C. Fenley ◽  
Sarah J. Bober ◽  
Mebane E. Powell ◽  
Jacquelin Berman ◽  
Barbara N. Altman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
New York ◽  
New York City ◽  
York City ◽  
The United States ◽  
Personal Care ◽  
Entry Level ◽  
Before And After ◽  
Item Knowledge

This article reports on the first 2 years of an ongoing project that examined the efficacy of a 10-hour dementia training provided to entry-level personal care aide (PCA) trainees from the Hispanic, White, African American, and Asian communities in New York City. Participants were enrolled in a 90-hour PCA training program offered by the New York City Department for the Aging and were either recipients of public assistance, displaced employees from September 11, or recent immigrants to the United States from China. Classes were conducted in Spanish, English, and Mandarin/Cantonese. An 11-item Knowledge of Alzheimer’s Disease instrument was developed for the purposes of this project and administered before and after the dementia training and at 3 months following graduation. All groups, regardless of language, showed a significant increase in knowledge of Alzheimer’s disease at the conclusion of the training and retention of this knowledge at 3 months follow-up. Age was strongly correlated with an increase in knowledge, while gender and education were not.

Lower cerebral oxygen utilization is associated with Alzheimer’s disease-related neurodegeneration and poorer cognitive performance among apolipoprotein E ε4 carriers

2021 ◽  
pp. 0271678X2110563
Author(s):  
W Hudson Robb ◽  
Omair A Khan ◽  
Humza A Ahmed ◽  
Judy Li ◽  
Elizabeth E Moore ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Episodic Memory ◽  
Apolipoprotein E ◽  
Cognitive Performance ◽  
Lateral Ventricle ◽  
Oxygen Metabolism ◽  
Cerebral Oxygen ◽  
P Values ◽  
Apoe Ε4

Oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen (CMRO2) are markers of cerebral oxygen homeostasis and metabolism that may offer insights into abnormal changes in brain aging. The present study cross-sectionally related OEF and CMRO2 to cognitive performance and structural neuroimaging variables among older adults (n = 246, 74 ± 7 years, 37% female) and tested whether apolipoprotein E ( APOE)-ε4 status modified these associations. Main effects of OEF and CMRO2 were null (p-values >0.06), and OEF interactions with APOE-ε4 status on cognitive and structural imaging outcomes were null (p-values >0.06). However, CMRO2 interacted with APOE-ε4 status on language (p = 0.002), executive function (p = 0.03), visuospatial (p = 0.005), and episodic memory performances (p = 0.03), and on hippocampal (p = 0.006) and inferior lateral ventricle volumes (p = 0.02). In stratified analyses, lower oxygen metabolism related to worse language (p = 0.02) and episodic memory performance (p = 0.03) among APOE-ε4 carriers only. Associations between CMRO2 and cognitive performance were primarily driven by APOE-ε4 carriers with existing cognitive impairment. Congruence across language and episodic memory results as well as hippocampal and inferior lateral ventricle volume findings suggest that APOE-ε4 may interact with cerebral oxygen metabolism in the pathogenesis of Alzheimer’s disease and related neurodegeneration.

Acetyl L-Carnitine Slows Decline in Younger Patients With Alzheimer's Disease: A Reanalysis of a Double-Blind, Placebo-Controlled Study Using the Trilinear Approach

1998 ◽  
Vol 10 (2) ◽  
pp. 193-203 ◽  
Author(s):  
John O. Brooks ◽  
Jerome A. Yesavage ◽  
Angelico Carta ◽  
Daniele Bravi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Average Rate ◽  
The United States ◽  
Rate Of Change ◽  
Disease Assessment ◽  
Controlled Study ◽  
Double Blind ◽  
Parallel Group ◽  
Longitudinal Effects

Objectives: To assess the longitudinal effects of acetyl-L-carnitine (ALC) on patients diagnosed with Alzheimer's disease. Design: Longitudinal, double-blind, parallel-group, placebocontrolled. Setting: Twenty-four outpatient sites across the United States. Participants: A total of 334 subjects diagnosed with probable Alzheimer's disease by NINCDS-ADRDA criteria. These data were originally reported by Thal and colleagues (1996). Measurements: Cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS) given every 3 months for 1 year. Results: The average rate of change was estimated using the trilinear approach, which allows for periods of both change and stability. Both the ALC group and the placebo group exhibited the same mean rate of change on the ADAS (0.68 points/month). However, a multiple regression analysis revealed a statistically significant Age × Drug interaction characterized by younger subjects benefiting more from ALC treatment than older subjects. Further analyses suggested that the optimal, though not statistically significant, cutpoint for ALC benefit was 61 years of age. Conclusions: ALC slows the progression of Alzheimer's disease in younger subjects, and the use of the trilinear approach to estimate the average rate of change may prove valuable in pharmacological trials.

Sign in / Sign up

Export Citation Format

Share Document